View Document Preview and Link Document Date: 2014-03-26 09:09:49 Open Document File Size: 405,57 KB Share Result on Facebook
City Geneva / Nagelkerke / Espinal / Rotterdam / Stockholm / Perucci / Surveillancerapport / The Hague / Haas / Amsterdam / Bilthoven / / Company National Reference Laboratory / Gageldonk-Lafeber AB / National Mycobacteria Reference Laboratory / SPSS / Lung Disease Working Group / / Continent Europe / / Country Netherlands / India / Nederland / / / Facility National Institute / / MedicalCondition TB / M. tuberculosis / pulmonary / infections / XDR-TB / resistant M. tuberculosis / drug-resistant tuberculosis / multidrug-resistant tuberculosis / Mycobacterium tuberculosis / infection / Infectious disease / extensively drug-resistant tuberculosis / tuberculosis / / MedicalTreatment vaccination / / Organization World Health Organization / National Science Foundation / National Institute for Public Health and the Environment / KNCV Tuberculosis Foundation / Tuberculosis Foundation / European Union / Dutch Foundation / / Person de Beer / Erika Slump / Marianne van der Sande / Wim van der Hoek / Hanna Guimaraes / Jan van de Kassteele / Van Soolingen / Van Deun / Van Embden / Henrieke Schimmel / / Position PM / van Embden JD / representative / / Product kanamycin / ofloxacin / linezolid / clarithromycin / isoniazid / pyrazinamide / AntiTuberculosis Drug / ciprofloxacin / / ProvinceOrState New Jersey / Maryland / Prince Edward Island / California / Massachusetts / / PublishedMedium PLoS One / / Region Sub-Saharan Africa / central Europe / central Asia / eastern Europe / / Technology pdf / http / / URL http / SocialTag 
Research articles Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011 C Ruesen ()1, A B van Gageldonk-Lafeber1, G de Vries1,2, C G Erkens2, J van Rest1,2, H